Evidence map›Paper›PMID 39913247›Full record

ArticleBrain : a journal of neurology2025

Parkinson's disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss.

Axel Chemla, Giuseppe Arena, Ginevra Sacripanti, Kyriaki Barmpa, Alise Zagare, Pierre Garcia, Vyron Gorgogietas, Paul Antony, Jochen Ohnmacht, Alexandre Baron and 10 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Species-dependent activities of the PINK1-parkin axis.Translational neurodegeneration · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Axel ChemlaLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.ORCID 0000-0001-8758-5424
Giuseppe ArenaLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-2398-5503
Ginevra SacripantiLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.
Kyriaki BarmpaLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.
Alise ZagareLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-3724-540X
Pierre GarciaLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.
Vyron GorgogietasLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.
Paul AntonyLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.ORCID 0000-0002-0450-9301
Jochen OhnmachtTransversal Translational Medicine, Luxembourg Institute of Health (LIH), L-1445 Strassen, Luxembourg.ORCID 0000-0001-7109-6802
Alexandre BaronLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.
Jaqueline JungInstitute of Medical Genetics and Applied Genomics, University of Tübingen, 72076 Tübingen, Germany.
Frida Lind-Holm MogensenFaculty of Science, Technology and Medicine, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg.
Alessandro MichelucciDepartment of Cancer Research, Luxembourg Institute of Health (LIH), L-1210 Luxembourg, Luxembourg.
Anne-Marie MarzescoLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.
Manuel ButtiniLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-1805-0279
Thorsten SchmidtInstitute of Medical Genetics and Applied Genomics, University of Tübingen, 72076 Tübingen, Germany.ORCID 0000-0002-1862-655X
Anne GrünewaldLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.ORCID 0000-0002-4179-2994
Jens C SchwambornLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-4496-0559
Rejko KrügerLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.
Cláudia SaraivaLuxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-4866-8790

Funding

Fonds National de la Recherche Luxembourg C17/BM/11676395Fonds National de la Recherche Luxembourg C19/BM/13535609Horizon 2020 C21/BM/15850547Horizon 2020 PRIDE/14254520/I2TRONMichael J. Fox Foundation
6 · The paper itself

Abstract

The complex and heterogeneous nature of Parkinson's disease (PD) is still not fully understood. However, increasing evidence supports mitochondrial impairment as a major driver of neurodegeneration. Miro1, a mitochondrial GTPase encoded by the RHOT1 gene, is involved in mitochondrial transport, mitophagy and mitochondrial calcium buffering, and is therefore essential for maintaining mitochondrial homeostasis. Recently, Miro1 has been linked genetically and pathophysiologically to PD, further supported by the identification of heterozygous variants of Miro1 in patients. Herein, we used patient-derived cellular models alongside knock-in mice to investigate Miro1-dependent pathophysiological processes and molecular mechanisms underlying neurodegeneration in PD. Experimental work performed in induced pluripotent stem cell (iPSC)-derived models, including midbrain organoids and dopaminergic neuronal cell cultures from a PD patient carrying the p.R272Q Miro1 mutation as well as healthy and isogenic controls, indicated that the p.R272Q Miro1 mutation leads to increased oxidative stress, disrupted mitochondrial bioenergetics and altered cellular metabolism. These changes were accompanied by increased α-synuclein levels and a significant reduction of dopaminergic neurons. Moreover, the p.R272Q Miro1 mutation-located in the calcium-binding domain of the GTPase-disrupted calcium homeostasis, resulting in calcium-dependent activation of calpain proteases and the subsequent cleavage of α-synuclein. Knock-in mice expressing p.R285Q Miro1 (the murine orthologue of the human p.R272Q mutation) displayed accumulation of phosphorylated α-synuclein in the striatum and a significant loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by behavioural alterations. These findings demonstrate that mutant Miro1 is sufficient to comprehensively model PD-relevant phenotypes in vitro and in vivo, reinforcing its pivotal role in PD pathogenesis.

Indexed as

Dopaminergic NeuronsMitochondriaMitochondrial ProteinsParkinson Diseaserho GTP-Binding Proteinsalpha-SynucleinAnimalsFemaleHumansInduced Pluripotent Stem CellsMaleMiceMice, Inbred C57BLMutationOxidative Stressalpha-SynucleinMiro-1 protein, mouseMitochondrial Proteinsrho GTP-Binding ProteinsRHOT1 protein, humancalcium homeostasisknock-in miceneurodegenerationpatient-specific iPSC-derived modelsp.R272Q Miro1α-synuclein

Identifiers

PMID39913247
PMCPMC12493065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.